Getting risks right on inhaled corticosteroids and adrenal insufficiency

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 9-11

  Watkins, Laura ^a   Soriano, Joan B ^b   Mortimer, Kevin ^a,c  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b Epidemiology and Clinical Research   (Spain)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE;

ADRENAL INSUFFICIENCY; COMORBIDITY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EDITORIAL; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENAL INSUFFICIENCY; FEMALE; HUMANS; MALE;

EID: 84880169954     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00204212     Document Type: Editorial

References (17)

1. Addison T. On the constitutional and local effects of the disease of the supra-renal capsules. In: Wilks S, Daldy TM, eds. A Collection of the Published Writings of the Late Thomas Addison MD. London, New Sydenham Society, 1868; pp. 211-239.
2. Lapi F, Kezouh A, Suissa S, et al. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J 2013; 42: 79-86.
3. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61: 405-408. (Pubitemid 43723323)
4. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461. (Pubitemid 35440691)
5. Todd GR. Adrenal crisis due to inhaled steroids is underestimated. Arch Dis Child 2003; 88: 554-555. (Pubitemid 36648956)
6. Mydin HH. Case history: a case of adrenal insufficiency secondary to symbicort. InnovAiT 2010; 3: 182-183.
7. Denne C, Vogl-Voswinckel AE, Gruebl A, et al. Adrenal crisis caused by inhaled fluticasone in an adolescent with cystic fibrosis and advanced hepatopathy: a case report. Case Rep Pulmonol 2012; 2012: 913574.
8. Schwatz RH, Neacsu O, Ascher DP, et al. Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clin Pediatr (Phila) 2012; 51: 1184-1190.
9. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556-561. (Pubitemid 30611861)
10. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58: 258-260. (Pubitemid 36308006)
11. Mortimer KJ, Harrison TW, Tang Y, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006; 62: 412-419. (Pubitemid 44401524)
12. Donnelly R, Williams KM, Baker AB, et al. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med 1997; 156: 1746-1751. (Pubitemid 28011777)
13. Weiner P, Berar-Yanay N, Davidovich A, et al. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931-934. (Pubitemid 29491861)
14. Brosnan CM, Gowing NF. Addison's disease. BMJ 1996; 312: 1085-1087. (Pubitemid 26125139)
15. Shulman DI, Palmert MR, Kemp SF, et al. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007; 199: e484-e494. (Pubitemid 46397798)
16. Brodlie M, McKean MC. Strategies to screen for adrenal suppression in children with asthma: there is no consensus among UK centres. Thorax 2008; 63: 841-842.
17. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, Alfred A. Knopf, 2004.